LAURA
For stage III lung cancers with an EGFR mutation, a targeted pill after chemoradiation cut progression by more than 80%.
216 patients. PFS 39.1 vs 5.6 months (HR 0.16); OS immature but favourable. FDA approval September 2024. Replaces durvalumab consolidation in EGFR-mutant stage III disease.
- Median 39.1 vs 5.6 months with Osimertinib compared with Placebo; about 33.5 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 84 percent lower chance of the event at any given time (hazard ratio 0.16, likely range 0.1 to 0.24).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Unresectable stage III EGFR-mutant NSCLC after chemoradiation: osimertinib until progression vs placebo. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (EGFR); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
216 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (BICR)primary | Osimertinib | 143 | 39.1 months | 0.16 (0.1–0.24) | <0.001 | link |
| Placebo | 73 | 5.6 months |
Pages like this
not linked directly; found by shared links- PersonJean-Charles Soria
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PersonHelena A. Yu
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- ProductDacomitinib
Shares EGFR, Non-small-cell lung cancer.
- PersonJohn V. Heymach
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PersonMatthew Meyerson
Shares EGFR, Non-small-cell lung cancer.
- PersonDaniel A. Haber
Shares EGFR, Non-small-cell lung cancer.
- IdeactDNA-guided dose holidays for lung cancer targeted therapy
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PersonThomas J. Lynch Jr.
Shares EGFR, Non-small-cell lung cancer.